ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2025
Evaluation of the effects of rosmarinic acid on red blood cell deformability, morphology, and nitric oxide in rat lower limb skeletal muscle ischemia-reperfusion injury.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silencing of HAVCR2 Attenuates Skeletal Muscle Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress.Biochemical genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErythrocyte deformability, the ability of red blood cells to bend and twist as they pass through capillaries, is es-sential for tissue perfusion. This study investigates the effects and underlying mechanisms of rosmarinic acid treatment on erythrocyte deformability in rats subjected to lower limb ischemia-reperfusion injury.
methodsThe study was conducted on Wistar albino rats weighing 400-450 g. The rats were randomly divided into five groups: the control group with no treatment (C), the group receiving only the solvent dimethyl sulfoxide (DMSO), the ischemia-reperfusion group (IR) subjected to 90 minutes of ischemia followed by 90 minutes of reperfusion in the femoral artery of the lower limb, the rosmarinic acid control group (RA-C) to assess the effects of rosmarinic acid alone, and the group (IR+RA) in which rosmarinic acid was administered intraperitoneally one hour before the ischemia-reperfusion procedure. At the end of the experiment, intracardiac blood samples were collected. Analyses included May-Grünwald-Giemsa (MGG) staining, measurement of endothelial nitric oxide synthase (eNOS), erythrocyte deformability indexes, malondialdehyde (MDA), and superoxide dismutase (SOD) levels.
resultsSignificant findings were observed in the study. Erythrocyte deformability was statistically significantly improved in the group that received rosmarinic acid prior to ischemia-reperfusion compared to the group that underwent ischemia-reperfusion alone. Morphological changes of erythrocytes were also significantly better in the IR+RA group than in the IR group. Immunohistochemical analysis of eNOS staining revealed that eNOS activity was higher in the IR group compared to the IR+RA group. Malondialdehyde (MDA) levels were significantly elevated in the IR group compared to all other groups. Analysis of superoxide dismutase levels showed that the SOD levels in the IR+RA group were significantly higher than those in the other groups.
conclusionOur findings indicate that rosmarinic acid treatment administered prior to ischemia provides protective effects against erythrocyte deformation and morphological deterioration. It is suggested that the improvement in deformability may be mediated by increased SOD activity, which reduces reactive oxygen anions, by-products of nitric oxide (NO) production, thereby exerting an antioxidant effect and enhancing the beneficial actions of NO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.